Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy

Journal Article · Wed Jan 01 00:00:00 EST 1986 · Proc. Natl. Acad. Sci. U.S.A.; (United States)

DOI:https://doi.org/10.1073/pnas.83.2.474· OSTI ID:5802195

Kozak, R W; Atcher, R W; Gansow, O A; Friedman, A M; Hines, J J; Waldmann, T A

Anti-Tac, a monoclonal antibody directed to the human interleukin 2 (IL-2) receptor, has been successfully conjugated to the alpha-particle-emitting radionuclide bismuth-212 by use of a bifunctional ligand, the isobutylcarboxycarbonic anhydride of diethylenetriaminepentaacetic acid. The physical properties of 212Bi are appropriate for radioimmunotherapy in that it has a short half-life, deposits its high energy over a short distance, and can be obtained in large quantities from a radium generator. Antibody specific activities of 1-40 microCi/microgram (1 Ci = 37 GBq) were achieved. Specificity of the 212Bi-labeled anti-Tac was demonstrated for the IL-2 receptor-positive adult T-cell leukemia line HUT-102B2 by protein synthesis inhibition and clonogenic assays. Activity levels of 0.5 microCi or the equivalent of 12 rad/ml of alpha radiation targeted by anti-Tac eliminated greater than 98% the proliferative capabilities of HUT-102B2 cells with more modest effects on IL-2 receptor-negative cell lines. Specific cytotoxicity was blocked by excess unlabeled anti-Tac but not by human IgG. In addition, an irrelevant control monoclonal antibody of the same isotype labeled with 212Bi was unable to target alpha radiation to cell lines. Therefore, 212Bi-labeled anti-Tac is a potentially effective and specific immunocytotoxic reagent for the elimination of IL-2 receptor-positive cells. These experiments thus provide the scientific basis for use of alpha-particle-emitting radionuclides in immunotherapy.

• Research Organization: National Cancer Institute, Bethesda, MD
• OSTI ID: 5802195
• Journal Information: Proc. Natl. Acad. Sci. U.S.A.; (United States), Vol. 2
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
62 RADIOLOGY AND NUCLEAR MEDICINE
LEUKEMIA
RADIOTHERAPY
MONOCLONAL ANTIBODIES
SPECIFICITY
ALPHA PARTICLES
BISMUTH 212
IMMUNOTHERAPY
LABELLED COMPOUNDS
PATIENTS
RECEPTORS
USES
ALPHA DECAY RADIOISOTOPES
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BISMUTH ISOTOPES
CHARGED PARTICLES
DISEASES
HEAVY NUCLEI
HEMIC DISEASES
HOURS LIVING RADIOISOTOPES
ISOTOPES
MEDICINE
MEMBRANE PROTEINS
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANIC COMPOUNDS
PROTEINS
RADIOISOTOPES
RADIOLOGY
THERAPY
560161* - Radionuclide Effects
Kinetics
& Toxicology- Man
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)